The global continuous renal replacement therapy market revenue was around US$ 1.4 billion in 2022 and is estimated to reach US$ 2.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.7% during the forecast period from 2023 to 2031.
Continuous renal replacement therapy (CRRT) is a slow and smooth constant extracorporeal blood purification procedure. It is usually implemented over 24 hours to several days with slow removal of fluid and extra uremic toxins. This process is usually based on the physiological principles of ultrafiltration, diffusion, adsorption, and convection.
Market Driving Factors
Increasing preference for Continuous Venovenous Hemodiafiltration (CVVHDF) modality is the key trend in the market. This modality is being preferred in the management of critically sick patients with acute kidney injury due to the various benefits provided by Continuous Venovenous Hemodiafiltration, Furthermore, some of the benefits of this modality include more hemodynamic stability than Intermittent Hemodialysis (IHD), constant removal of fluid and uremic toxins and others.
Rapid launches and advancements are estimated to boost the market growth. This is because of immediate technological advances and the introduction of new creative products for this therapy surge its adoption in handling critically sick patients. Thus, the key players are concentrating on developing products tailored to distinct patient populations, such as pediatric patients to fulfill the constantly evolving demand for CRRT products. For instance, in December 2020, Medtronic launched the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine which is generally designed for neonatal and pediatric patients. This system is intended for usage in cases involving fluid-overloaded or acute kidney injury (AKI) patients needing hemodialysis or hemofiltration therapy, and it can be appropriate for patients weighing between 2.5-10 kilograms.
The high price associated with CRRT devices in developing nations is the key elements that limit market growth.
Regional Analysis
Asia-Pacific dominated the market in terms of the largest shares and is estimated to maintain its dominance. This can be primarily attributed to the surge in several initiatives along with improved investments for the overall R&D of CRRT products. Additionally, increased focus of leading manufacturers on extending their geographical existence in emerging nations.
North America is estimated to dominate the market in terms of the growth rate. This is owing to the high-unmet medical requirements of the target disease segment, such as hypertension, diabetes, and chronic kidney disease, connected with increasing healthcare expenses in the region.
Segmentation Insights
Modality Insight
The continuous venovenous hemofiltration (CVVH) segment dominates the market in terms of the largest shares. This is because it can remove large volumes of fluid while avoiding the hypotensive episodes induced by intermittent hemodialysis and its intermittent removal of large volumes of fluid which is increasing demand.
The continuous venovenous hemodiafiltration (CVVHDF) segment is expected to dominate the market in terms of growth rate. This is owing to the CVVHDF is an adequate treatment in patients suffering from acute renal failure. Furthermore, this therapy has various technical benefits and is appropriate for the aging population across the world.
Age Group Insight
The adult segment dominated the market in terms of shares. This can be largely attributed to the different regulatory approvals for the adult CRRT, and raised in the development of products for CRRT. Furthermore, the adoption of several growth strategies by different key players is estimated to create lucrative prospects in the segment.
Prominent Companies
Segmentation Outline
The global continuous renal replacement therapy market segmentation focuses on the Product, Modality, Age Group, and Region.
By Product
By Modality
By Age Group
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 DIALYSATES AND REPLACEMENT FLUIDS
5.3 DISPOSABLES
5.3.1 HEMOFILTERS
5.3.2 BLOODLINE SETS & TUBES
5.3.3 OTHERS
5.4 CRRT SYSTEMS
6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY
6.1 OVERVIEW
6.2 SLOW CONTINUOUS ULTRAFILTRATION (SCUF)
6.3 CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH)
6.4 CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF)
6.5 CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD)
7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP
7.1 OVERVIEW
7.2 ADULTS
7.3 PEDIATRICS
8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 B. BRAUN MELSUNGEN AG
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ANJUE MEDICAL EQUIPMENT CO. LTD
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ASAHI KASEI CORPORATION
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 MEDICA S.P.A
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 MEDICAL COMPONENTS INC
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 BAXTER INTERNATIONAL
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 MEDTRONIC PLC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 INFOMED S.A.
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 TORAY INDUSTRIES INC.
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 NIPRO CORPORATION
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 CYTOSORBENTS
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 SWS HEMODIALYSIS CARE
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 FRESENIUS MEDICAL CARE
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 MEDITES PHARMA SPOL
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 NIKKISO CO. LTD
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.17 NINGBO TIANYI MEDICAL DEVICES
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved